gene

CS

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about CS: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

48Connections

30Hypotheses

12Analyses

40Outgoing

8Incoming

5Experiments

15Debates

Summary

CS encodes citrate synthase, a key mitochondrial enzyme in the TCA cycle with important roles in neuronal energy metabolism and neurodegeneration.

View on Wiki →

No AI portrait yet

🧬 Gene Info

Gene Symbol	CS
Full Name	Citrate Synthase
Chromosome	12p15
Protein Type	Enzyme
Function	is a nuclear-encoded gene located on chromosome 12p15 that encodes citrate synthase, a key mitochondrial enzyme that catalyzes the first committed step of the citric acid cycle (TCA cycle).
Primary Expression	virtually all tissues with high activity in: - Heart: Highest expression (high energy demand) - Liver: Central metabolic hub - Kidney: Act
Amino Acids	466 aa
UniProt ID	O75390
NCBI Gene ID	1451
Ensembl ID	ENSG00000143228
OMIM	118950
GeneCards	CS
Human Protein Atlas	CS
N-terminal domain	Contains the binding site for acetyl-CoA
C-terminal domain	Contains the oxaloacetate binding site
Associated Diseases	Huntington's disease, neurodegeneration
Known Drugs/Compounds	quercetin, rapamycin
Interactions	AKT, BDNF, CALCOCO2, CDKN1A, CDKN2A, CXCL1
KG Connections	48 knowledge graph edges
Databases	GeneCards HPA STRING

🔮 Predicted Structure: CS — AlphaFold O75390 Click to expand

AI-predicted structure from AlphaFold | Powered by Mol*

Wiki Pages (21)

Knowledge base pages for this entity

Canonical Page

Pathway Diagram

flowchart TD
    N0["CS"]
    N1["neurodegeneration"]
    N0 -->|"associated with"| N1
    N2["PINK1"]
    N0 -->|"activates"| N2
    N3["PRKN"]
    N0 -->|"activates"| N3
    N4["senescence"]
    N0 -->|"participates in"| N4
    N5["CXCL1"]
    N0 -->|"activates"| N5
    N6["CXCL8"]
    N0 -->|"activates"| N6
    N7["GLB1"]
    N0 -->|"activates"| N7
    N8["LC3"]
    N0 -->|"activates"| N8

    classDef gene fill:#1a3a2a,stroke:#4caf50,color:#e0e0e0
    classDef protein fill:#1a2a3a,stroke:#4fc3f7,color:#e0e0e0
    classDef disease fill:#3a1a1a,stroke:#ef5350,color:#e0e0e0
    classDef pathway fill:#2a1a3a,stroke:#ce93d8,color:#e0e0e0
    classDef mechanism fill:#2a2a1a,stroke:#ffd54f,color:#e0e0e0
    classDef drug fill:#1a2a2a,stroke:#26c6da,color:#e0e0e0
    classDef cell_type fill:#2a1a2a,stroke:#ab47bc,color:#e0e0e0
    classDef phenotype fill:#2a2a1a,stroke:#ffa726,color:#e0e0e0
    classDef process fill:#1a2a2a,stroke:#66bb6a,color:#e0e0e0
    classDef biological_process fill:#1a2a2a,stroke:#66bb6a,color:#e0e0e0
    classDef concept fill:#1a1a2a,stroke:#7986cb,color:#e0e0e0
    classDef entity fill:#1a2a3a,stroke:#4fc3f7,color:#e0e0e0
    classDef therapeutic fill:#1a2a2a,stroke:#26c6da,color:#e0e0e0
    classDef index fill:#1a1a2a,stroke:#7986cb,color:#e0e0e0
    class N0 gene
    class N1 disease
    class N2 gene
    class N3 gene
    class N4 pathway
    class N5 gene
    class N6 gene
    class N7 gene
    class N8 gene

Outgoing (40)

Target	Relation	Type	Str
neurodegeneration	associated_with	disease	0.70
MFF	associated_with	gene	0.60
MFN2	associated_with	gene	0.60
OPA1	associated_with	gene	0.60
PI3K	activates	gene	0.60
PYCARD	activates	gene	0.60
neurodegeneration	activates	disease	0.60
DRP1	associated_with	gene	0.60
neurodegeneration	causes	disease	0.60
IGF1R	associated_with	gene	0.60
Huntington's disease	associated_with	disease	0.60
RNA	regulates	gene	0.60
GSH	activates	gene	0.60
lipid metabolism	participates_in	pathway	0.60
RNA	associated_with	gene	0.60
senescence	participates_in	pathway	0.60
MAP1LC3	activates	gene	0.60
Alzheimer's disease	activates	disease	0.60
autophagy pathway	participates_in	pathway	0.60
apoptosis pathway	participates_in	pathway	0.60
oxidative stress response	participates_in	pathway	0.60
ubiquitin-proteasome	participates_in	pathway	0.60
mitochondrial function	participates_in	pathway	0.60
PI3K-AKT-mTOR signaling	participates_in	pathway	0.60
ROS	activates	gene	0.60
PINK1	activates	gene	0.60
PRKN	activates	gene	0.60
CXCL1	activates	gene	0.60
CXCL8	activates	gene	0.60
GLB1	activates	gene	0.60
LC3	activates	gene	0.60
MTOR	activates	gene	0.60
NDP52	activates	gene	0.60
OPTN	activates	gene	0.60
PTEN	activates	gene	0.60
TNF	activates	gene	0.60
TH	associated_with	gene	0.60
neuroinflammation	activates	disease	0.60
stem cells	expressed_in	cell_type	0.55
macrophages	expressed_in	cell_type	0.55

Incoming (8)

Source	Relation	Type	Str
AKT	activates	gene	0.60
CALCOCO2	activates	gene	0.60
CDKN1A	activates	gene	0.60
CDKN2A	activates	gene	0.60
BDNF	activates	gene	0.60
rapamycin	targets	drug	0.60
quercetin	targets	drug	0.60
AGER	associated_with	gene	0.35

Targeting Hypotheses (30)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
CSF1R Inhibition-Mediated Microglial Replacement as a State	0.898	neurodegeneration	How do different microglial subtypes (DA
Closed-loop tACS targeting EC-II SST interneurons to block t	0.896	Alzheimer's disease	Circuit-level neural dynamics in neurode
Closed-loop tACS targeting EC-II PV interneurons to suppress	0.857	Alzheimer's disease	Circuit-level neural dynamics in neurode
ACSL4-Driven Ferroptotic Priming in Disease-Associated Micro	0.847	Alzheimer's Disease	Cell type vulnerability in Alzheimers Di
Closed-loop tACS targeting EC-II parvalbumin interneurons to	0.831	Alzheimer's disease	Circuit-level neural dynamics in neurode

Elevated CSF/Serum Albumin Quotient Predicts Neurodegenerati	0.825	-	What blood-brain barrier permeability ch
HSPB1 Phosphorylation Mimetics to Promote Protective TDP-43	0.820	neurodegeneration	What is the therapeutic window between i
CSF1R-TREM2 Co-Agonism for Sustained Microglial Expansion	0.808	neurodegeneration	TREM2 agonism vs antagonism in DAM micro
CSF sTREM2 as Pharmacodynamic Biomarker for Therapeutic Wind	0.801	neuroimmunology	TREM2 in Alzheimer's Disease: Mechanisms
ACSL4-Ferroptotic Priming in Stressed Oligodendrocytes Drive	0.801	Alzheimer's Disease	Cell type vulnerability in Alzheimers Di
40 Hz Gamma Entrainment Gates ACSL4-Mediated Ferroptotic Pri	0.801	Alzheimer's Disease	Cell type vulnerability in Alzheimers Di
Selective APOE4 Degradation via Proteolysis Targeting Chimer	0.795	neurodegeneration	APOE4 structural biology and therapeutic
Senescent Microglia Resolution via Maresins-Senolytics Combi	0.784	neurodegeneration	Neuroinflammation resolution mechanisms
Closed-loop tACS targeting entorhinal cortex layer II SST in	0.784	Alzheimer's disease	Circuit-level neural dynamics in neurode
ACSL4-Driven Ferroptotic Priming in Disease-Associated Oligo	0.779	Alzheimer's Disease	Cell type vulnerability in Alzheimers Di
Tau/MAP6 ratio as a master switch for microtubule dynamics p	0.750	neurodegeneration	View
TREM2-CSF1R Cross-Talk in Microglial Metabolic Reprogramming	0.748	neurodegeneration	Gene expression changes in aging mouse b
STING Antagonists as ALS Therapeutics: Drug Repurposing	0.740	neuroinflammation	How does chronic cGAS/STING activation d
Integrated Multi-Analyte CSF Panel Combining YKL-40, sTREM2,	0.730	biomarkers	What biomarkers can reliably detect micr
Interfacial Lipid Mimetics to Disrupt Domain Interaction	0.723	neurodegeneration	APOE4 structural biology and therapeutic
CSF YKL-40 as a Priming-Specific Chitinase Marker	0.710	biomarkers	What biomarkers can reliably detect micr
TDP-43 condensation thermodynamics as a therapeutic target a	0.710	neuroscience	How can subcellular compartmentalization
Lysosomal Positioning Dynamics Modulation	0.686	neurodegeneration	Autophagy-lysosome pathway convergence a
ACSL4 lipid remodeling creates ferroptosis-prone ALS membran	0.685	neurodegeneration	Ferroptosis in ALS motor neuron vulnerab
GPX4 Selenopeptide Mimetics as Neuroprotective Ferroptosis B	0.680	-	Ferroptosis in ALS and motor neuron dise
CSF Soluble TREM2 Fragment Ratio as Priming State Indicator	0.680	biomarkers	What biomarkers can reliably detect micr
CSF/Plasma AQP4 Polarization Index as a Novel Biomarker of A	0.680	-	What blood-brain barrier permeability ch
Lipid Droplet Dynamics as Phenotype Switches	0.666	neurodegeneration	Astrocyte reactivity subtypes in neurode
TNF-α/NF-κB Axis Upregulates P2RY12 in VSMCs	0.650	neurodegeneration	What determines P2RY12 receptor expressi
Matrix Metalloproteinase-9/TIMP-1 Ratio in CSF Identifies Pr	0.650	-	What blood-brain barrier permeability ch

Mentioning Analyses (12)

Scientific analyses that reference this entity

Can CSF p-tau217 normalization serve as a reliable surrogate endpoint for determ

neurodegeneration | 2026-04-26 | 7 hypotheses Top: 0.560

What blood-brain barrier permeability changes serve as early biomarkers for neur

neurodegeneration | 2026-04-26 | 8 hypotheses Top: 0.915

What blood-brain barrier permeability changes serve as early biomarkers for neur

neurodegeneration | 2026-04-26 | 8 hypotheses Top: 0.720

Blood-brain barrier permeability changes as early biomarkers for neurodegenerati

neurodegeneration | 2026-04-26 | 3 hypotheses Top: 0.750

Blood-brain barrier permeability changes as early biomarkers for neurodegenerati

neurodegeneration | 2026-04-26 | 5 hypotheses Top: 0.712

Experiments (5)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Model	Status	Est. Cost
SAHA@LIPO-ANG2 therapeutic efficacy in 5xFAD mice	validation	Alzheimer's disease	0.900	5xFAD transgenic mice	proposed	N/A
Transcriptomic profiling and differential expression analysis	exploratory	Alzheimer's disease	0.900	1-month-old APP/PS1 mice cereb	proposed	N/A
Autophagy receptor identification for stress granule elimination	exploratory	neurodegenerative diseases	0.900	cultured cells under arsenite	proposed	N/A
SIRPα modulation in mouse models of Alzheimer's disease	validation	Alzheimer's disease	0.900	mouse models of Alzheimer's di	proposed	N/A
Microglial SIRPα expression in human Alzheimer's disease tissue	exploratory	Alzheimer's disease	0.800	human brain tissue	proposed	N/A

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
Transcriptomic cytoarchitecture reveals principles of human neocortex organizati [PMID:37824655]	Jorstad NL, Close J, Johansen N, Yanny A	Science	2023	186
FAK/SRC-JNK axis promotes ferroptosis via upregulating ACSL4 expression. [PMID:41862445]	Qin J, Ma S, Wang J, Huang S, Luan J, He	Cell death & disease	2026	0
Quercetin attenuates ox-LDL-induced endothelial injury by regulating ferroptosis [PMID:41902795]	Gao C, Liu B, Zhang R, Tian J, Xin H	Toxicology mechanisms and meth	2026	0
NEDD8 promotes the ferritinophagy and ferroptosis of neurons in ischemic stroke [PMID:41662890]	Rao W, Huang Y, Li J, Chen Q, Sun J et a	J Stroke Cerebrovasc Dis	2026	0
Inhibition of Ferroptosis in Prostatitis Model by Low Intensity Extracorporeal S [PMID:41714892]	Lin D, Li K, Kuang W, Chen Z, Zhang M	World J Mens Health	2026	0
Deciphering sorafenib resistance in hepatocellular carcinoma via ferroptotic mec [PMID:41763496]	Che L, Zhu L, Zhou L, Zhou Y	Biochim Biophys Acta Rev Cance	2026	0
B4GALT1 deficiency attenuates steatohepatitis by regulating the PPARγ/ACSL4 axis [PMID:41860570]	Chien Y, Xia R, Zhou D, Ai Y, Wu L et al	Hepatol Commun	2026	0
Unraveling the impact of risk factors on the ferroptosis-Alzheimer's disease lin [PMID:41498558]	Singh P, Rath SL	Journal of Alzheimer's disease	2026	0
Resveratrol Alleviates Intervertebral Disc Degeneration by Targeting NCOA4-Media [PMID:41873334]	Song C, Wu X, Chen C, Shen B, He Y, Liu	Drug design, development and t	2026	0
Pan-PPAR agonist bezafibrate alleviates psoriasis by suppressing LCN2-dependent [PMID:41662914]	["Xin R", "Zhang J", "Zhang Y", "Dai M",	Free radical biology & medicin	2026	0
Acteoside alleviates sepsis-induced acute lung injury by activating the Nrf2 pat [PMID:41895086]	Wang Y, Zhang W, Zhang M, Zhu Y, Wang W,	Tissue & cell	2026	0
Ferroptosis and microglial polarization in retinal vein occlusion: pathological [PMID:41924362]	Xu J, Sun M, Wang C, Ju P, Guan XD, Xie	International journal of ophth	2026	0
Dynamics and Impact of Repopulating Microglia Following Oligodendroglial Damage. [PMID:41645884]	Di Pietro AA, Thomas L, Pasquini LA	J Neurochem	2026	0
Temporal modulation of microglial repopulation attenuates retinal degeneration i [PMID:41690604]	Zhang W, Bian B, Ren C	Neurobiol Dis	2026	0
The impact of CSF1R inhibitor-mediated microglial depletion in rodent models of [PMID:41822299]	Ferreira AFF, Santos-Silva AC, Muratori	Front Aging Neurosci	2026	0
Enhancing TREM2 expression activates microglia and modestly mitigates tau pathol [PMID:40122810]	["Chen Kai", "Li Fuyao", "Zhang Shuwen",	Journal of neuroinflammation	2025	0
Melatonin Alleviates Erastin-Induced Cell Death by Inhibiting Ferroptosis and Am [PMID:40442550]	Wongjaikam S, Siengdee P, Somnus A, Govi	Neurotoxicity research	2025	0
Acyl-CoA synthetase long-chain family member 4-A novel prognostic marker in cuta [PMID:41918944]	Paria S, Lapides R, Saravi B, Rajagopal	Frontiers in medicine	2025	0
Microglial exosome TREM2 ameliorates ferroptosis and neuroinflammation in alzhei [PMID:40640358]	Zhu L, Zhou T, Wu L, Zhu X, Chen L, Zhan	Scientific reports	2025	0
Microbiota-derived lysophosphatidylcholine alleviates Alzheimer's disease pathol [PMID:39510074]	["Zha Xu", "Liu Xicheng", "Wei Mengping"	Cell metabolism	2025	0

Debates (15)

Multi-agent debates referencing this entity

Can CSF p-tau217 normalization serve as a reliable surrogate endpoint for determ

active · Rounds: 4 · Score: 1.00 · 2026-04-26

Formal debate: plasma GFAP separates causal from compensatory states in: Blood-b

active · Rounds: 3 · Score: 0.75 · 2026-04-26

Formal debate: tight-junction remodeling is the actionable driver in: Blood-brai

active · Rounds: 3 · Score: 0.75 · 2026-04-26

What blood-brain barrier permeability changes serve as early biomarkers for neur

active · Rounds: 4 · Score: 1.00 · 2026-04-26

What blood-brain barrier permeability changes serve as early biomarkers for neur

active · Rounds: 4 · Score: 1.00 · 2026-04-26

Blood-brain barrier permeability changes as early biomarkers for neurodegenerati

closed · Rounds: 4 · Score: 0.78 · 2026-04-26

Blood-brain barrier permeability changes as early biomarkers for neurodegenerati

active · Rounds: 7 · Score: 0.00 · 2026-04-26

Which specific CSF molecular components are essential for maintaining disease-re

active · Rounds: 4 · Score: 0.66 · 2026-04-25

Which proteins are differentially expressed in AD CSF and brain tissue, and do t

closed · Rounds: 4 · Score: 0.30 · 2026-04-21

What are the key metabolic alterations detectable in brain tissue, CSF, and bloo

closed · Rounds: 4 · Score: 0.50 · 2026-04-18

Related Research

Hypotheses and analyses mentioning CS in their description or question text

Elevated CSF/Serum Albumin Quotient Predicts Neurodegeneration Progression Indep

Score: 0.825 · unknown disease · 2026-04-26

Serum albumin is synthesized exclusively by the liver and absent from CNS under normal BBB. When barrier permeability in

HSPB1 Phosphorylation Mimetics to Promote Protective TDP-43 Liquid-Liquid Phase

Score: 0.820 · neurodegeneration · 2026-04-13

## Mechanistic Overview HSPB1 Phosphorylation Mimetics to Promote Protective TDP-43 Liquid-Liquid Phase Separation start

CSF1R-TREM2 Co-Agonism for Sustained Microglial Expansion

Score: 0.808 · neurodegeneration · 2026-04-16

## Mechanistic Overview CSF1R-TREM2 Co-Agonism for Sustained Microglial Expansion starts from the claim that modulating

CSF sTREM2 as Pharmacodynamic Biomarker for Therapeutic Window Identification

Score: 0.801 · neuroimmunology · 2026-04-15

## Mechanistic Overview CSF sTREM2 as Pharmacodynamic Biomarker for Therapeutic Window Identification starts from the cl

ACSL4-Ferroptotic Priming in Stressed Oligodendrocytes Drives White Matter Degen

Score: 0.801 · Alzheimer's Disease · 2026-04-05

## Mechanistic Overview ACSL4-Ferroptotic Priming in Stressed Oligodendrocytes Drives White Matter Degeneration in Alzhe

40 Hz Gamma Entrainment Gates ACSL4-Mediated Ferroptotic Priming to Selectively

Score: 0.801 · Alzheimer's Disease · 2026-04-05

## Mechanistic Overview 40 Hz Gamma Entrainment Gates ACSL4-Mediated Ferroptotic Priming to Selectively Eliminate Diseas

Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs)

Score: 0.795 · neurodegeneration · 2026-04-02

## Mechanistic Overview Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs) starts from the claim t

Senescent Microglia Resolution via Maresins-Senolytics Combination

Score: 0.784 · neurodegeneration · 2026-04-02

## Mechanistic Overview Senescent Microglia Resolution via Maresins-Senolytics Combination starts from the claim that mo

Closed-loop tACS targeting entorhinal cortex layer II SST interneurons to activa

Score: 0.784 · Alzheimer's disease · 2026-04-05

## Mechanistic Overview Closed-loop tACS targeting entorhinal cortex layer II SST interneurons to activate AMPK-autophag

ACSL4-Driven Ferroptotic Priming in Disease-Associated Oligodendrocytes Underlie

Score: 0.779 · Alzheimer's Disease · 2026-04-05

## Mechanistic Overview ACSL4-Driven Ferroptotic Priming in Disease-Associated Oligodendrocytes Underlies White Matter D

Tau/MAP6 ratio as a master switch for microtubule dynamics plasticity

Score: 0.750 · neurodegeneration · 2026-04-25

The relative abundance of tau versus MAP6 on individual microtubules determines the balance between stable and labile do

TREM2-CSF1R Cross-Talk in Microglial Metabolic Reprogramming

Score: 0.748 · neurodegeneration · 2026-04-12

**Molecular Mechanism and Rationale** The TREM2-CSF1R metabolic cross-talk hypothesis centers on the intricate molecula

STING Antagonists as ALS Therapeutics: Drug Repurposing

Score: 0.740 · neuroinflammation · 2026-04-21

## **Molecular Mechanism and Rationale** The cGAS-STING (Cyclic GMP-AMP Synthase - Stimulator of Interferon Genes) path

Integrated Multi-Analyte CSF Panel Combining YKL-40, sTREM2, and Neurogranin

Score: 0.730 · biomarkers · 2026-04-22

## Mechanistic Overview Integrated Multi-Analyte CSF Panel Combining YKL-40, sTREM2, and Neurogranin starts from the cla

Interfacial Lipid Mimetics to Disrupt Domain Interaction

Score: 0.723 · neurodegeneration · 2026-04-02

## Mechanistic Overview Interfacial Lipid Mimetics to Disrupt Domain Interaction starts from the claim that modulating A

CS

Understanding Entity Pages

Summary

Wiki Pages (21)

CS Gene

CSF Neurofilament Light Chain (NfL) in Neurodegeneration

Cerebrospinal Fluid (CSF) Biomarkers Overview

Cerebrospinal Fluid (CSF) Biomarkers in Neurodegeneration

HLCS Gene

CSF1R Inhibitors for Parkinson's Disease

Mitochondria-Lysosome Contact Sites (MLCS) in Neurodegeneration

Mitochondria-Lysosome Contact Site (MLCS) Dysfunction Hypothesis in Parkinson's Disease

SORCS2 Gene

CSF-1R Inhibitors

CSNK1D - Casein Kinase 1 Delta

NPTX1 and NPTXR CSF Markers Predict Alzheimer's Disease Progression

Microglial Proteins in CSF Reveal AD Progression States

CSF Biomarkers for Corticobasal Syndrome and Progressive Supranuclear Palsy

Cysteine String Protein (CSP)

MLCS Quantification in Parkinson's Disease

Glymphatic and CSF Dynamics Enhancement for CBS/PSP

MLCS Research Methods in iPSC-Derived Dopaminergic Neurons

CSF Dynamics and Glymphatic Therapy in CBS/PSP

BCS1L Gene

CSF1R-Targeted Microglia Therapy

Pathway Diagram

Outgoing (40)

Incoming (8)

Targeting Hypotheses (30)

Mentioning Analyses (12)

Can CSF p-tau217 normalization serve as a reliable surrogate endpoint for determ

What blood-brain barrier permeability changes serve as early biomarkers for neur

What blood-brain barrier permeability changes serve as early biomarkers for neur

Blood-brain barrier permeability changes as early biomarkers for neurodegenerati

Blood-brain barrier permeability changes as early biomarkers for neurodegenerati

Which specific CSF molecular components are essential for maintaining disease-re

Proteomics Differential Expression in AD CSF and Brain Tissue

Metabolomic signatures of neurodegeneration: metabolic reprogramming in aging br

What determines the GPX4/ACSL4 balance that switches microglia from protective t

What are the specific circulating factors in exercise-conditioned plasma that me

Neuroinflammation and microglial priming in early Alzheimer's Disease

Extracellular vesicle biomarkers for early AD detection

Experiments (5)

Related Papers (20)

Debates (15)

Can CSF p-tau217 normalization serve as a reliable surrogate endpoint for determ

Formal debate: plasma GFAP separates causal from compensatory states in: Blood-b

Formal debate: tight-junction remodeling is the actionable driver in: Blood-brai

What blood-brain barrier permeability changes serve as early biomarkers for neur

What blood-brain barrier permeability changes serve as early biomarkers for neur

Blood-brain barrier permeability changes as early biomarkers for neurodegenerati

Blood-brain barrier permeability changes as early biomarkers for neurodegenerati

Which specific CSF molecular components are essential for maintaining disease-re

Which proteins are differentially expressed in AD CSF and brain tissue, and do t

What are the key metabolic alterations detectable in brain tissue, CSF, and bloo

Related Research

Elevated CSF/Serum Albumin Quotient Predicts Neurodegeneration Progression Indep

HSPB1 Phosphorylation Mimetics to Promote Protective TDP-43 Liquid-Liquid Phase

CSF1R-TREM2 Co-Agonism for Sustained Microglial Expansion

CSF sTREM2 as Pharmacodynamic Biomarker for Therapeutic Window Identification

ACSL4-Ferroptotic Priming in Stressed Oligodendrocytes Drives White Matter Degen

40 Hz Gamma Entrainment Gates ACSL4-Mediated Ferroptotic Priming to Selectively

Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs)

Senescent Microglia Resolution via Maresins-Senolytics Combination

Closed-loop tACS targeting entorhinal cortex layer II SST interneurons to activa

ACSL4-Driven Ferroptotic Priming in Disease-Associated Oligodendrocytes Underlie

Tau/MAP6 ratio as a master switch for microtubule dynamics plasticity

TREM2-CSF1R Cross-Talk in Microglial Metabolic Reprogramming

STING Antagonists as ALS Therapeutics: Drug Repurposing

Integrated Multi-Analyte CSF Panel Combining YKL-40, sTREM2, and Neurogranin

Interfacial Lipid Mimetics to Disrupt Domain Interaction